Stock Events

Stock Events

Argenica Therapeutics Limited 

A$0.18
6
+A$0+2.94% Today

Statistics

Day High
0.19
Day Low
0.18
52W High
0.83
52W Low
0.14
Volume
26,220
Avg. Volume
-
Mkt Cap
22.48M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

9FebExpected
Q2 2022
Q4 2023
Q2 2024
Q3 2024
Q4 2024
Q2 2025
Q4 2025
-0.03
-0.02
-0.01
0
Expected EPS
N/A
Actual EPS
-0.027965614520250003

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-14.34MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow AGN.AU. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Biogen
BIIB
Mkt Cap27.06B
Lilly(Eli) &
LLY
Mkt Cap789.69B
Eli Lilly and Company has extensive research in neurodegenerative diseases and stroke, overlapping with Argenica's therapeutic areas.
Novartis
NVS
Mkt Cap280.79B
Novartis AG has a significant presence in neuroscience and treatments for neurological conditions, competing in the same therapeutic space as Argenica.
Pfizer
PFE
Mkt Cap153.59B
Pfizer Inc. is involved in developing treatments for neurological disorders, including stroke, which is a direct competition to Argenica's research focus.
Roche
RHHBY
Mkt Cap332.61B
Roche Holding AG has a strong portfolio in neurology and brain health, making it a competitor in the neurological treatment market.
Astrazeneca
AZN
Mkt Cap294.17B
AstraZeneca PLC has initiatives in developing therapies for stroke and neurological disorders, areas where Argenica is also active.
Merck
MRK
Mkt Cap276.38B
Merck & Co., Inc. works on neuroprotective drugs and treatments for brain injuries, competing with Argenica's stroke recovery solutions.
GSK
GSK
Mkt Cap108.66B
GlaxoSmithKline plc invests in neurological health, including stroke recovery and prevention, aligning as a competitor to Argenica.
Abbott Laboratories
ABT
Mkt Cap158.36B
Abbott Laboratories offers various medical devices and pharmaceuticals for neurological conditions, indirectly competing with Argenica's therapeutic approach.
Johnson & Johnson
JNJ
Mkt Cap547.64B
Johnson & Johnson engages in the development of treatments for neurodegenerative diseases, overlapping with Argenica's focus areas.

About

Argenica Therapeutics Limited, a biotechnology company, engages in the research and development of neuroprotective therapeutic drugs in Australia. Its lead product candidate is ARG-007, a neuroprotective peptide candidate, which is in phase 2 clinical trial to reduce brain tissue death after stroke and other types of brain injury. The company was incorporated in 2019 and is based in Nedlands, Australia.
Show more...
CEO
Dr. Liz Dallimore B.Sc., M.B.A., Ph.D.
Country
Australia
ISIN
AU0000150328

Listings

AU
AU
AGN.AU

0 Comments

Share your thoughts

FAQ

What is Argenica Therapeutics Limited stock price today?▼
The current price of AGN.AU is A$0.18 AUD — it has increased by +2.94% in the past 24 hours. Watch Argenica Therapeutics Limited stock price performance more closely on the chart.
What is Argenica Therapeutics Limited stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Argenica Therapeutics Limited stocks are traded under the ticker AGN.AU.
Is Argenica Therapeutics Limited stock price growing?▼
AGN.AU stock has fallen by -5.41% compared to the previous week, the month change is a +2.94% rise, over the last year Argenica Therapeutics Limited has showed a -74.07% decrease.
What is Argenica Therapeutics Limited market cap?▼
Today Argenica Therapeutics Limited has the market capitalization of 22.48M
When is the next Argenica Therapeutics Limited earnings date?▼
Argenica Therapeutics Limited is going to release the next earnings report on August 26, 2026.
What were Argenica Therapeutics Limited earnings last quarter?▼
AGN.AU earnings for the last quarter are -0.03 AUD per share, whereas the estimation was N/A AUD resulting in a N/A surprise. The estimated earnings for the next quarter are N/A AUD per share.
What is Argenica Therapeutics Limited revenue for the last year?▼
Argenica Therapeutics Limited revenue for the last year amounts to 0 AUD.
What is Argenica Therapeutics Limited net income for the last year?▼
AGN.AU net income for the last year is -14.34M AUD.
In which sector is Argenica Therapeutics Limited located?▼
Argenica Therapeutics Limited operates in the Health & Wellness sector.
When did Argenica Therapeutics Limited complete a stock split?▼
Argenica Therapeutics Limited has not had any recent stock splits.
Where is Argenica Therapeutics Limited headquartered?▼
Argenica Therapeutics Limited is headquartered in Nedlands, Australia.